Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and concurrent private placement expected to raise $132 million to fund combined operations through the second half of 2028.
Key Highlights:
- Completed all-stock acquisition of Kira, combining complementary pipelines to advance high-value immunology programs.
- Entered securities purchase agreement for non-voting convertible preferred stock expected to raise approximately $132 million gross.
- Out-licensed KP-301 and KP-402 to Mirador for $12 million upfront plus potential milestone and sales payments.
- Pro-forma cash, including financing and out-license proceeds, expected to fund operations and multiple clinical milestones through H2 2028.
- Combined Company plans near-term clinical readouts and regulatory milestones: KP-104 interim renal data in Q4 2026 and Phase 2/3 planning for PNH in H1 2027.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.